Physician profile
Win Kyaw
NPI 1700049236
$7,482.72
in general payments reported to CMS, 2019-2025
48 companies · $931 in 2025
The $931 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $823 · 2021: $1,038 · 2022: $1,097 · 2023: $1,032 · 2024: $1,452 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.77 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $932.16 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $636.47 | 2019-2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $468.34 | 2019-2025 | |
| Novo Nordisk INC | $409.25 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $383.85 | 2020-2025 | Jesduvroq, Benlysta |
| Horizon Therapeutics Plc | $331.20 | 2020-2023 | Krystexxa |
| Vifor Pharma, INC. | $327.49 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $290.39 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $269.53 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.47 | 2021-2025 | Jardiance |
| Travere Therapeutics, INC. | $219.09 | 2022-2025 | |
| Ardelyx, INC. | $214.89 | 2023-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $207.53 | 2021-2024 | Lupkynis |
| Lilly USA, LLC | $194.25 | 2020-2025 | Zepbound, Mounjaro |
| Calliditas Therapeutics US INC. | $155.45 | 2023-2025 | Tarpeyo |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $154.14 | 2019-2025 | Ultomiris, Strensiq |
| Xeris Pharmaceuticals, INC. | $139.37 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $123.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $117.54 | 2019-2022 | |
| Genzyme Corporation | $113.00 | 2020-2024 | |
| Akebia Therapeutics INC | $108.50 | 2019-2025 | Vafseo |
| Recordati_rare_diseases_inc. | $107.65 | 2021-2025 | Isturisa, Signifor Lar, Cystadrops |
| Opko Pharmaceuticals, LLC | $94.25 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $87.46 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $85.83 | 2019 | |
| Mannkind Corporation | $85.74 | 2021-2025 | |
| Radius Health, INC. | $85.20 | 2019-2023 | Tymlos |
| Dexcom, INC. | $83.88 | 2024-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $70.39 | 2023-2024 | Crysvita |
| Amarin Pharma, INC. | $63.50 | 2020-2021 | |
| Averitas Pharma INC. | $61.89 | 2025 | Qutenza |
| Corcept Therapeutics | $60.69 | 2020-2021 | |
| Scpharmaceuticals INC. | $59.66 | 2025 | |
| Amag Pharmaceuticals, INC. | $58.13 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $50.25 | 2023-2025 | Yorvipath |
| Medtronic, INC. | $49.93 | 2021-2023 | Ellipsys Vascular Access System |
| Tandem Diabetes Care, INC. | $47.26 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $37.81 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $37.63 | 2020-2022 | |
| Fisher Scientific Company L.L.C. | $34.84 | 2019 | |
| Cequr Corporation | $28.37 | 2022-2023 | Cequr Simplicity |
| Insulet Corporation | $24.05 | 2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $23.43 | 2022 | |
| Medtronic Minimed, INC. | $21.02 | 2019 | |
| Cormedix INC. | $20.44 | 2024 | Defencath |
| Ionis Pharmaceuticals, INC. | $19.52 | 2025 | Tryngolza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Bigfoot Biomedical INC | $16.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Win Kyaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.